Munich, Germany – The European Society of Cardiology (ESC) Congress 2026, a pivotal gathering for global cardiology leaders and pharmaceutical innovators, is currently underway in Munich, Germany. This year’s congress is proving to be a fertile ground for the dissemination of critical late-stage clinical trial data, offering unprecedented insights into novel therapeutic approaches and the evolving landscape of cardiovascular medicine. Clinical Trials Arena is providing comprehensive coverage of these significant developments, highlighting key readouts that promise to reshape patient care and pharmaceutical strategies.
Cytokinetics’ Myqorzo Achieves Landmark Phase III Success in Non-Obstructive Hypertrophic Cardiomyopathy
In a development poised to offer a new lifeline to patients suffering from symptomatic, non-obstructive hypertrophic cardiomyopathy (HCM), Cytokinetics’ cardiac myostatin inhibitor, Myqorzo (aficamten), has demonstrated statistically significant efficacy in its Phase III ACACIA-HCM study. Presented in a highly anticipated Hot Line session at ESC 2026, the trial’s results suggest Myqorzo may soon become the first approved therapy specifically targeting this debilitating condition.
Chronology of the ACACIA-HCM Study:
The ACACIA-HCM study (NCT06081894) was meticulously designed to evaluate the efficacy and safety of Myqorzo in patients diagnosed with symptomatic, non-obstructive HCM. The trial enrolled a significant cohort of patients, aiming to provide robust evidence for the drug’s potential in this underserved patient population.
Supporting Data and Primary Endpoint Achievement:
The core findings of the ACACIA-HCM study revealed that Myqorzo met one of its primary endpoints by delivering a substantial 11.4-point improvement in clinical measures of cardiomyopathy at the 36-week mark. This improvement was measured against a 8.4-point increase observed in the placebo group, underscoring the drug’s meaningful impact. Principal investigator Dr. Ahmad Masri highlighted that the benefits of Myqorzo began to manifest as early as 12 weeks into treatment, indicating a relatively rapid onset of action.
Furthermore, at the same 36-week time point, patients receiving Myqorzo experienced a significant enhancement in maximal exercise performance. Their peak oxygen uptake (peak VO2) improved by an average of 0.64 mL/kg/min, a marked contrast to the near-unchanged peak volumes observed in the placebo arm. This achievement fulfilled the study’s secondary main goal, reinforcing the drug’s capacity to improve functional capacity in these patients.
Official Responses and Expert Commentary:
Dr. Masri expressed immense optimism regarding the study’s outcomes, stating that the results provide "really positive news" for individuals living with symptomatic, non-obstructive HCM. He emphasized the historical significance of these findings, marking the first instance where a targeted medication has demonstrated clinically meaningful improvements in both symptoms and exercise capacity.
Cytokinetics is likely to view these results as a pivotal step towards expanding Myqorzo’s therapeutic label. The drug previously secured US regulatory approval in December 2025 for obstructive HCM, and the ACACIA-HCM success provides a strong foundation for its potential use in the non-obstructive variant of the disease.
Implications for the Cardiovascular Market:
Hypertrophic cardiomyopathy (HCM) is a genetic disorder characterized by the thickening and stiffening of the heart muscle, which can impair its ability to pump blood effectively, particularly during physical exertion. Current estimates suggest that approximately one in 500 individuals have HCM, with a significant proportion, ranging from 30% to 70%, presenting with the non-obstructive form of the disease.
The successful outcome of the ACACIA-HCM trial positions Myqorzo as a potentially game-changing therapy for this patient group. GlobalData, the parent company of Clinical Trials Arena, forecasts that Myqorzo is on track to achieve blockbuster status by 2029, reflecting the significant unmet medical need and the anticipated market penetration of this novel treatment. This development is expected to intensify competition in the cardiovascular therapeutics market and drive further innovation in the treatment of rare genetic cardiac conditions.
Amgen’s Repatha: A Tale of Two Outcomes in Postmarketing Cardiovascular Study
The ESC 2026 Congress has also been the stage for the presentation of mixed results from a crucial postmarketing study involving Amgen’s highly regarded injectable PCSK9 inhibitor, Repatha (evolocumab). The Phase IV AMUNDSEN study (NCT04951856) investigated the impact of Repatha in patients who had experienced a heart attack and undergone procedures to open narrowed coronary arteries.
Chronology of the AMUNDSEN Study:
The AMUNDSEN study was designed as an interventional Phase IV trial to assess the real-world effectiveness of Repatha in helping patients achieve their target low-density lipoprotein cholesterol (LDL-C) levels, compared to standard of care (SoC). The study specifically enrolled patients who had recently been hospitalized for a myocardial infarction and were subsequently treated with percutaneous coronary intervention (PCI).
Supporting Data and Dual Findings:
The study yielded significant positive results concerning Repatha’s ability to lower LDL-C. At 12 months, an impressive 82% of patients treated with Repatha achieved their LDL-C endpoint, a substantial increase compared to the 40% observed in the standard care group. Furthermore, those achieving the LDL-C target did so considerably faster with Repatha, reaching their goal in an average of nine weeks, versus 19 weeks in the standard care arm. This clearly demonstrates Repatha’s potent LDL-C-lowering capabilities in this high-risk patient population.
However, the study’s findings took a more complex turn when assessing clinical outcomes. Despite the marked reduction in LDL-C levels, Repatha did not translate into a statistically significant difference in the rates of all-cause mortality or cardiovascular hospitalizations between the Repatha and standard care groups. This outcome suggests that while Repatha excels at lipid management, its immediate impact on broader clinical cardiovascular events in this specific post-heart attack scenario warrants further investigation.
Official Responses and Expert Commentary:
Dr. Gilles Montalescot from Hôpital Pitié-Salpêtrière, a leading investigator in the AMUNDSEN study, offered a nuanced interpretation of the data. He posited that the lack of significant improvement in cardiovascular outcomes might indicate that Repatha "may not have early clinically meaningful pleiotropic effects and the benefit of lipid lowering may require more time." This statement suggests that the cardiovascular benefits of aggressive LDL-C lowering with Repatha might manifest over a longer follow-up period, or that other factors play a more dominant role in the immediate post-MI period.
Implications for the Cardiovascular Market:
The mixed results for Repatha come at a time of increasing market penetration for PCSK9 inhibitors, despite their higher cost compared to traditional statins. The recent approval of MSD’s Lipfendra, the first oral PCSK9-targeting therapy, has further energized the market, with experts expressing considerable enthusiasm for its therapeutic potential.
The AMUNDSEN study’s findings will undoubtedly fuel ongoing discussions about the optimal role and timing of PCSK9 inhibitors in secondary prevention strategies. While their efficacy in lipid reduction is undisputed, the balance between cost, LDL-C lowering, and demonstrable clinical outcome improvement will remain a key area of focus for clinicians and payers alike. The long-term implications of Repatha’s pleiotropic effects, beyond LDL-C reduction, will likely be a subject of ongoing research and clinical debate.
Bristol Myers Squibb Details Phase III Milvexian Setback, But Offers Glimmers of Hope
Bristol Myers Squibb (BMS) has provided detailed results from the Phase III LIBREXIA-ACS study, which evaluated its investigational Factor Xa (FXa) inhibitor, milvexian, for the treatment of acute coronary syndrome (ACS). While the study was previously terminated due to a lacklustre interim analysis, the newly released data offers some insights that could positively influence BMS’s other ongoing milvexian development programs.
Chronology of the LIBREXIA-ACS Study and Termination:
The LIBREXIA-ACS study (NCT05754957) was designed to assess the efficacy and safety of milvexian in patients experiencing acute coronary syndromes. However, an interim analysis revealed that the drug did not demonstrate a significant advantage over placebo in reducing major adverse cardiovascular events. Based on these findings, BMS made the decision to terminate the study prematurely.
Supporting Data and Nuanced Findings:
A subsequent, more in-depth analysis of the data collected from the LIBREXIA-ACS study has shed further light on the trial’s outcomes. The analysis revealed that the rates of cardiovascular death, heart attack, or ischemic stroke were remarkably similar between the milvexian and placebo treatment groups. Specifically, such events occurred in 5.4% of patients receiving milvexian and 5.1% of those on placebo, at a median follow-up period of 10 months. This lack of separation on the primary efficacy endpoint was the basis for the study’s termination.
However, the detailed results also offered a more encouraging perspective for BMS’s broader milvexian pipeline. Crucially, the study observed no significant differences in the rates of intracranial or fatal bleeding between the milvexian and placebo groups. This finding is particularly significant given that bleeding complications are a primary concern with anticoagulant therapies, and the absence of an increased bleeding risk with milvexian is a reassuring signal.
Official Responses and Expert Commentary:
Dr. Gabriel Steg, the principal investigator of LIBREXIA-ACS, characterized the lack of increased bleeding as "reassuring." He further emphasized that there are distinct differences between the LIBREXIA-ACS study and the ongoing LIBREXIA AF (atrial fibrillation) and LIBREXIA Stroke trials. These distinctions include variations in patient populations, the underlying disease pathology, and the specific endpoints being evaluated, suggesting that the results from LIBREXIA-ACS may not be directly extrapolated to these other trials.
Implications for the Cardiovascular Market:
BMS is pinning significant hopes on milvexian, a next-generation anticoagulant and FXIa inhibitor, to succeed its blockbuster predecessor, Eliquis (apixaban), as the latter approaches its patent cliff and loss of market exclusivity. The performance of milvexian in its ongoing development programs is therefore of paramount importance to BMS’s future revenue streams and its competitive position in the anticoagulant market.
While the LIBREXIA-ACS results represent a setback for milvexian’s potential use in ACS, the reassuring safety profile regarding bleeding events offers a glimmer of hope for its other indications. Analysts have demonstrated keen interest in milvexian, as evidenced by numerous questions posed during recent BMS earnings calls. The success of milvexian in atrial fibrillation and stroke prevention trials will be critical in determining its overall market impact and its ability to fill the void left by Eliquis. The continued development of novel anticoagulants remains a key area of research and commercial interest, driven by the persistent burden of thrombotic and bleeding events in cardiovascular disease.
The ESC Congress 2026 continues to be a crucial platform for sharing groundbreaking research and fostering advancements in cardiovascular medicine. The data presented here, from novel therapeutics for rare conditions to nuanced evaluations of established drug classes, underscores the dynamic nature of cardiology and the relentless pursuit of improved patient outcomes. Clinical Trials Arena remains committed to providing timely and comprehensive coverage of these pivotal scientific developments.
About the Author
